Jacobson Pharma Awards HK$607 Million Tai Po Facility Infrastructure Contract

The latest update is out from Jacobson Pharma Corporation Limited ( (HK:2633) ).

Jacobson Pharma has accepted a HK$607.2 million tender for special infrastructure development and specialised facilities works at its Tai Po Factory, to be carried out by an independent main contractor selected via open tender. The project, funded by internal resources, government funding and bank borrowings, is expected to take 745 days from 9 April 2026 and aims to enhance the group’s production infrastructure, supporting operational capacity and long-term growth.

The contractor was chosen from five bidders based on price, qualifications, experience, resources and construction programme, with its strong track record and ability to work near existing structures within an accelerated timeframe expected to cut costs and shorten the construction period. The transaction meets the criteria for a discloseable transaction under Hong Kong listing rules, underscoring the materiality of this capital investment for Jacobson Pharma’s facility expansion and stakeholders’ interest in its execution.

The most recent analyst rating on (HK:2633) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Jacobson Pharma Corporation Limited stock, see the HK:2633 Stock Forecast page.

More about Jacobson Pharma Corporation Limited

Jacobson Pharma Corporation Limited is a Hong Kong-listed pharmaceutical company engaged in manufacturing and supplying pharmaceutical products. Through its subsidiaries, the group develops and operates specialised production facilities to support its portfolio and expand infrastructure for advanced pharmaceutical manufacturing in Hong Kong and the region.

Average Trading Volume: 391,386

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.34B

For a thorough assessment of 2633 stock, go to TipRanks’ Stock Analysis page.